Search results for: 'Software-as-a-Service china'

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

The immunoassay and clinical chemistry market is the highest share contributor for the total in vitro diagnostics (IVD) market. Globally valued at $28.7 billion in 2019, this market segment contributes 37.6% of the total IVD market of $76.3 billion. Within the high-medium to low analyzer segment, there are over 40 companies globally. Of these, 14 c...

17 May 2024  |  Global  |  Market Research

Growth Opportunities in US and European Hospital Workflow Digital Platforms and Solutions in Acute Care, Forecast to 2028

Integration of Clinical and Operational Solutions to Improve Patient and Provider Experience

Infographics

×

The COVID-19 pandemic exposed cracks in healthcare s clinical, financial, and operational processes. Efficiency has become a major focus as hospital systems strive to stitch healthcare networks together. From simple technological or software solutions to complex AI-driven predictive algorithms, healthcare institutions aim to improve automation and ...

Single cell genomic and proteomics tools have gained significant importance in the past 2 years. The year 2018 was particularly very active with a lot of platforms made available by both established life sciences tools companies and start-ups. 10X Genomics and Fluidigm have demonstrated the potential for high-throughput single cell applications. Th...

23 Aug 2022  |  North America  |  Frost Radar

Frost Radar™: US Liquid Biopsy, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comp...

This Frost Radar benchmarks companies offering digital pathology solutions for hospitals and laboratories and discusses opportunities in clinical, pharma, CRO, and research applications. Digital pathology solutions cover all aspects of workflow including sample collection and preparation, image acquisition and integrated image storage, and anal...

The change in reimbursement for diagnostic testing, pressure from PAMA, regulatory trends in Europe, demand for large-scale testing, shift to precision diagnostics, emerging companies, and evolving business models demand assessing portfolio, evaluating competitor strategies, and exploring opportunities for business growth. The competitive nature of...

10 Jan 2018  |  Asia Pacific  |  Market Research

APAC Biosimilar Market, Forecast 2025

Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth

Infographics

×

Key Issues Addressed Key Benefits

Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Korea, o...

Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastructure relies on an extensive supply chain involving ...